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Abstract
A key challenge in drug delivery systems is the real time monitoring of  delivered drug and
subsequent response. Recent advancement in nanotechnology has enabled the design and preclinical
implementation of  novel drug delivery systems (DDS) with theranostic abilities. Herein, fluorescent
cerium fluoride (CeF3) nanoparticles (nps) were synthesized and their surface modified with a coat of
polyethylenimine (PEI). Thereafter, Methotrexate was conjugated upon it through glutaraldehyde cross-
linking for a pH-sensitive release. This was followed by the addition of  a Hyaluronic acid (HA) receptor
via  1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide  and  N-hydroxysuccinimide  (EDC-NHS)
chemistry to achieve a possible active drug targeting system. The obtained drug delivery nano-agent
retains  and  exhibits  unique  photo-luminescent  properties  attributed  to  the  nps  while  exhibiting
potential theranostic capabilities.
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 1. Introduction
 1.1. Cancer Research
Cancer is one of  the most popular diseases on the face of  this earth that has existed for almost
the entirety  of  human history.  With over  200 known variants,  it  is  a  group of  diseases  involving
abnormal growth of  cells with the potential plausibility of  invading or spreading to healthier cells or
parts of  the body. Lacking in specific fingerprints and having the widest spectra of  causalities, it is next
to impossible to prove the cause for a particular cancer regardless of  its type. [1] Therefore, a lot of
research is under way to identify the causes of  the disease as well as in developing strategies for its
prevention, diagnosis, treatment and subsequent cure.
Although a  number  of  treatment  options  exist  for  cancers  such as  surgery,  chemotherapy,
radiation therapy, gene therapy, immunotherapy, photo-dynamic therapy, targeted therapy, palliative care
etc.,[2-13] they still do not accommodate for the different phenotypes observed in individual cases or
provide a generic therapeutic to be followed. Also, cancer is a class of  disease, it can also be argued that
it will be be highly unlikely that a single cure for cancer will ever come to exist. However, research
continues in hopes of  achieving a “silver bullet” treatment technique that can be employed over a
majority of  the cases.
Due to the dynamic nature of  the disease, Cancer Research is one of  the most funded forms of
medical  research  in  the  world  with  billions  spent  worldwide  every  year.  Recent  advancements  in
molecular  and cellular  biology has lead to a revolution bringing about better  treatments through a
variety of  preclinical and clinical trials reducing the risk quotient involved with the treatment of  the
disease with every passing day.[14] Perhaps one day,  the silver bullet  treatment that  every researcher
working in the field envisions might even become a reality with all the awareness, effort and investment
being put into the field.
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 1.2. Drug Delivery Systems for Cancer
There exists a multitude of  therapeutic techniques for cancer but drug delivery remains one of
the most prominent. This is due to the fact that drugs may be used to limit or inhibit the spread of  the
disease as well as sometimes used as a measure to cure it. Depending upon individual requirements
drug delivery systems tend to involve either deliverance of  the drug directly into the affected area or to
an  affected  area  through  utilization  of  a  carrier.  With  advancements  in  technology,  the  carrier
techniques have been offered additional functionalities such as specific molecular targeting enabling
higher efficiencies. Current efforts include development of  novel DDS that activate only in the target
area with sustained or controllable release.[15-22]
 1.3. Theranostics
Theranostics is the field of  science pertaining to the combination of  diagnosis and therapeutics.
It involves utilization of  agents of  drug delivery that are capable of  carrying drugs to their  target
locations while offering limited but crucial diagnostic information of  the environment around them in
real-time.  Recently,  biomedical  research  pertaining  to  DDS  have  come  to  realize  the  immense
significance of  controlled targeted release of  drugs along with the ability to monitor drug effect and
the patient response in real-time. Researchers now realize that the characteristics shall enable physicians
to  make  changes  in  therapeutic  techniques  employed  based  upon  feedback  received,  while
simultaneously, reducing damage to healthy cells and organs from drug side-effects.  However, such
theranostic capabilities are yet largely limited to in-vitro environments and preclinical studies due to the
extraordinarily enormous amount of  research required to get such an agent to be safe and approved for
human use. Nevertheless, the contribution of  the same within its current limited domain is not to be
overlooked as it still enables one to gather more information regarding individual phenotypes exhibited
by patients and their possible response to a therapeutic method. [23-33]
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 1.4. pH sensitive glutaraldehyde cross-linking
Glutaraldehyde is one of  the most versatile cross-linking reagents that is prominently utilized in
biochemistry.  Present  in  at  least  thirteen  different  forms  based  on  solution  conditions,  there  is
substantial literature available regarding the use of  the reagent for various cross-linking applications
with various carbohydrates, lipids, nucleic acids, enzymes, and other soluble and insoluble molecules.
Owing to many discrepancies and the unique characteristics of  each moiety linked with the reagent
however,  cross-linking  procedures  are  largely  developed  through  empirical  observations  and  its
subsequent properties are also tested in the same manner. However, many research articles elucidate
cases wherein the cross-linking acts in a pH sensitive manner with respect to linking efficiencies and
reversibility of  the link formed. [33-35]
 1.5. Hyaluronic Acid – Cancer receptor
Hyaluronic  acid  is  a  unique nonsulfated glycosaminoglycan  which  is  formed in the  plasma
membrane instead of  the Golgi.  Through literature it  has been mentioned that the macromolecule
significantly contributes to cell proliferation and migration and has also been linked to the progression
of  many malignant tumours. For cancer, HA acts as a receptor enabling targeting due to the over-
expression of  CD44 glycoprotein in cancer cells which is recognized as a major receptor of  HA. [35-44]
 1.6. Objective
Through this  thesis,  an attempt at  creating a novel DDS for Cancer,  utilizing CeF3 nps is
described. The naked lanthanide nps have previously been associated with providing protection against
oxidative stress as well as being toxic. The host material was selected under the assumption that the
same characteristic shall be reproduced in preclinical safety studies even when functionalized as a drug
delivery agent. If  realized, it would entail the safeguard of  healthy cells from apoptosis due to oxidative
stress from introduction of  nanoparticles into their environment. Furthermore, the understanding that
CeF3 can act as a scintillator makes it  all  the more desirable as a drug carrier for the purpose of
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theranostic applications; at least within the scope of  preclinical studies.  
Utilizing  PEI,  the  surface  of  the  nanoparticles  synthesized  were  modified  such  that
glutaraldehyde cross-linking of  the amine groups in PEI with the amine group in the Cancer drug –
Methotrexate - was enabled. This entailed that the conjugation of  the drug was pH-sensitive which
consequently  will  allow controlled  release  within  Cancer  cells  alone.  This  would  eventually  reduce
chances  of  damaging  healthier  cells  rendering  the  drug  more  effective  than when delivered  using
conventional means.  
In  order  to  impart  a  targeting  functionality  to  the  DDS,  Hyaluronic  acid  was  added  as  a
receptor.  It  is  well  established  in  literature  as  a  targeting  compound  for  Cancer  cells  and  it  was
implemented to the system via EDC-NHS coupling. With the addition of  the final component, the
novel DDS that was planned was completed. With unique optical properties of  CeF3 nps coupled with
the enhancements, it is believed that the DDS may prove beneficial in theranostic applications across
preclinical screens; with significant possibility of  the same to be transferable to in-vivo conditions upon
optimization. 
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 2. Materials and Methods
 2.1. Reagents
Ammonium fluoride (NH4F), Cerium nitrate hexahydrate (Ce(NO3).6H2O), Polyethylenimine
((C2H5N)n),  Methotrexate  (C20H22N8O5),  25%  Glutaraldehyde  solution  (C5H8O2),  Hyaluronic  acid
sodium salt (C14H22NNaO11),  Sodium chloride (NaCl), Potassium chloride (KCl), Disodium phosphate
(Na2HPO4),  Monopotassium  phosphate  (KH2PO4),  35%  Hydrochloric  acid,  1-Ethyl-3-(3-
dimethylaminopropyl)-carbodiimide  (EDC),  N-hydroxysuccinimide  (NHS)  were  all  purchased  from
Sigma Aldrich. Absolute Ethanol was supplied by Changshu Hongsheng Fine Chemical Co., Ltd. De-
ionized (DI) water was procured from a pre-existing distillation unit within the department.
 2.2. Experiment
 a) Preparation of  Phosphate Buffered Saline (PBS) solution
1 L PBS solution with pH 7.4 was prepared as per the recipe elucidated in Cold Spring Harbor
Protocols. 250 mL of  which was later on adjusted to pH 5.0.[45]
 b) Synthesis of  Cerium fluoride nps
Cerium fluoride nanoparticles were synthesized following a slightly modified version of  the
simple co-precipitation route employed by Varun et. al.[46] wherein 40 mM cerium nitrate hexahydrate
dissolved in ethanol was mixed with hot (~70º C) 120 mM ammonium fluoride hexahydrate dissolved
in DI water and stirred continuously for 10-15 minutes.
 c) Surface Modification and Drug Loading 
To the freshly prepared solution with cerium fluoride nps precipitation, 1% PEI in DI water
was made and added in a 1:25 ratio by solvent. It was then left on stirring for nearly 24 hours in order
to coat the nps with the polymer coating. 1 mM of  the drug was then added to the solution and left to
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stir for another hour for a uniform dispersion. This was followed by the addition of  nearly 1.5 times
absolute ethanol to the amount of  solvent present in the solution in order to attain desolvation. After
another hour of  stirring, a few drops of  25% glutaraldehyde solution was added and the solution was
left to stir  for about 12 hours. The resulting solution was made to precipitate through heating and
addition of  ethanol (if  required) and thereafter washed with ethanol. It was then re-dispersed in DI
water/PBS as per requirement.
 d) Preparation and coupling of  Hyaluronic acid
A 10 mM solution of  Hyaluronic Acid Sodium Salt was prepared in 10 mM solution  of  HCl.
Thereafter 10 mM of  EDC and NHS were added to the solution and stirred for about 5 minutes
before  adding  immediately  to  the  drug-PEI-nps  conjugate  dispersion prepared  earlier  and left  for
stirring for nearly 24 hours. The final product was thereafter washed with hot DI water. It was then re-
dispersed in DI water/PBS as per the requirement.
 e) Drug release studies
1 mM of  the drug was dispersed in 10 mL of  pH 7.4 PBS solution and 300 uL of  it was further
diluted in 1.2 mL of  pH 7.4 PBS solution. This was then characterized using UV-Vis spectroscopy to
ascertain maximum peak of  the drug. The supernatant post washings were collected and air dried. It
was then re-dispersed in 10 mL of  pH 7.4 PBS and then further diluted by taking 300 ul in 1.2 mL of
pH 7.4  PBS before  characterization  using  UV-Vis  to  evaluate  drug  loss  during  drug  loading  and
receptor attachment. Thereafter, a certain weight of  the prepared agent was dispersed in 10 mL of  pH
7.4 PBS and loaded into a dialysis membrane. This was suspended in 50 mL solution of  pH 7.4 PBS
for nearly a day in order to remove any drug releasing at that pH. Immediately after this, the agent
loaded membrane was suspended in 150 mL of  pH 5.0 PBS solution. 300 uL samples were taken out
on a time lapse and the removed PBS was replenished in order to carry out drug release studies by
creating  dilutions  in  1.2  mL  of  pH  5.0  PBS  solution  and  then  characterizing  using  UV-Vis
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spectroscopy.  The same weight  of  the  drug was directly  dispersed in 10 mL of  pH 5.0  PBS and
characterized for drug max value.
 2.3. Characterization
UV-Vis absorption spectra were acquired by using the Cary 100 UV-Vis Spectrophotometer by
Agilent  Technologies.  X-ray  powder  Diffraction (XRD) Spectroscopy was carried out on a  Philips
powder diffractometer PW 3040/60 X'Pert Pro with Cu Kα radiation to determine nps characteristics.
Photo-luminescence (PL) for the emission spectra of  the sample was carried out on a Horiba Jobin-
Yvon FluroLog-3 model.  A Bruker Hyperion 3000 Microscope with a Vertex 80 Fourier transform
infra-red (FTIR) system was used for obtaining FTIR spectra. The data was then plotted using the open
source software GNU-PLOT.
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Figure 1: Schematic representation of proposed agent preparation.
 3. Results
From the image, it is clear that cerium fluoride nanoparticle were formed with an average size
range of  10-20 nms. Upon close inspection, translucent enclosures can be seen around the particles
which  might  be  the  PEI  layer  functionalized  with  the  drug  and  receptor.  Upon  long  periods  of
exposure,  it  was  observed  that  this  layer  would  turn  invisble  and  therefore  remained  mostly
unobservable.  The hypothesis  for the phenomenon is  that  the organic PEI layer  might be getting
burned off  owing to the high intensity electron beam of  the TEM. It was the major reason why images
of  CeF3 nanoparticle  with PEI coating was not included since the images would go blank within
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Figure 2: TEM image. a) Drug-PEI-nps without HA, scale: 20 nm b) Drug-PEI-nps without HA, 
scale: 50 nm c) Drug-PEI-nps without HA, scale: 100 nm d) Drug-PEI-nps with HA, scale: 20 nm 
e) Drug-PEI-nps with HA, scale: 50 nm f) Drug-PEI-nps with HA, scale: 100 nm.
seconds of  exposure. With the functionalization of  the organic layer however, the same phenomenon
was limited, perhaps due to the quenching of  the light sensitive PEI. 
The graph above shows excitation peak is in line with CeF3 nanoparticles i.e., close to 250 nm
and shows a rise in absorbency with the addition of  HA receptor. This entails that the agent would
absorb more light resulting in a weaker emission spectra of  the nanoparticle core due to the presence
of  larger molecules over the surface. However, the agent does retain characteristics of  its core which is
evident from an almost similar UV-Vis pattern.
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Figure 3: Graph plot showing data acquired from UV-Vis Spectroscopy for prepared Samples. 
(Units: Absorbance – a.u.; Wavelength - nm)
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The XRD data of  regular naked CeF3 nps received coincided with the XRD peaks found in
literature. However, when in conjugated form, the peaks were rather indiscernible owing to the high
level of  noise from the organic polymer attached. It can also be argued that the crystalline structure is
no longer prominent in the agent which results in such a trend in the XRD graph above. 
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Figure 4: XRD plot of prepared nanoparticle samples in native as well as conjugated form. 
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The PL emission spectra of  the resulting agent was coherent with the PL spectra of  CeF3 nps
in literature. Although there was a significant reduction in the emission intensity, it put to rest concerns
of  the emission being completely quenched and resulting in the agent being useless for theranostic
purposes. In order to enhance the emission of  the agent, the core nps system may be doped with
impurities such as Europium or Terbium which are almost the same size and are in all probability non-
toxic in nature.
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Figure 5: PL of samples without and with HA.
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FTIR plot comparing samples with and without HA shows an increase in the 3500-3300 nm
region post addition which could be due to the increase of  O-H and N-H bonds due to the addition of
the glycosaminoglycan. The amine and alcohol or phenol stretch is quite significant as inferred from
the plot above. An increase in the amide C=O stretch is also observed. There was a significant decrease
in the peak in the 1300-1400 nm region however, the trend is pretty much similar. Since the region
close to 1200 nm is known as the fingerprint region, it can be hypothesised that although a lot of  C-O
bonds might have been lost in the process of  HA addition, the agent retained the drug. For further
clarification, a standard FTIR spectra of  naked CeF3 nps and one with PEI attached could be taken
alongside and compared.
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Figure 6: FTIR plot of prepared samples without and with HA.
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Drug release studies were conducted over a time lapse of  – 5 minutes, 10 minutes, 15 minutes,
30 minutes, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 18 hours, 24 hours, 30 hours, 36 hours, 48
hours, 72 hours, 96 hours, 120 hours and 140 hours. An extended release was not expected. However,
since it was observed upon characterization. Fluctuations in drug release data might be a result of  a
combination of  human error, instrumental error as well as re-absorption of  the drug by the agent.
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Figure 7: Drug release studies over time-lapse. (Units: Absorbance – a.u.; Wavelength - nm)
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Discussions and Conclusions
Although  the  agent  offers  promising  results  in  terms  of  drug  release  as  well  as
photoluminescence,  and core  being lanthanide  would  offer  obstruction  to  X-rays  offering  another
method of  agent monitoring within the body, it is yet to be tested for toxicity. The behaviour of  the
prepared agent is but anyone's guess unless a few toxicity assays are performed to determine their
safety. Nevertheless, the system is proposed to be useful within the scope of  preclinical safety studies
wherein cultured cells  are utilized. In this manner,  newly formulated drugs can be tested in a safe
manner  without  animal  or  human  casualties.  Further  tests  are  required  to  conclude  the  targeting
capabilities owing to HA.
Due to the dynamic and versatile nature of  the agent, it can be highly tuned to suit specific
needs. The luminescence can be enhanced via means of  introducing impurities of  other lanthanide
elements. Also,  the application method can be varied.  Addition of  an external encapsulation could
enable drug delivery in an oral form. Transferring the agent onto a thin film can also help in facilitating
topical approaches to certain malignant tumours on the skin surface. Since nanoparticle systems have a
high penetrative capability, it can be a good way to combat skin cancer in many individuals and also in a
very cheap and easy way.
In conclusion, a novel DDS was designed utilizing nps from the lanthanide series as the core
element.  The  results  observed  seem  rather  promising  towards  evolving  the  current  theranostic
techniques available and might prove crucial in the creation of  a marketable technology. However, an
immense amount of  research would be required prior to technology transfer including a number of
toxicological screens, preclinical and clinical trials along with a number of  approvals. Nevertheless, if
realized, the technology developed shall revolutionize modern medicine.
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